Submit

Login Login

Register Register

Home / Journals / OR / Online First / doi:10.32604/or.2026.084396
Journal Menu
Special Issues
Table of Content

All issues

Online First

2026

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

Past Issues

Open Access

ARTICLE

Autophagy Inhibition Enhances the Antitumor Efficacy of MET Targeting in MET-High Pancreatic Cancer

Zhiyi Min1,2, Chunbin Wang3, Tongjin Yin4, Wanyan Jiao4, Dandan Zhou3, Xuyao Zhang2,*, Junli Cui5,*, Zhe Ding1,*
1 Department of Pharmacy, Yancheng Third People’s Hospital (The Affiliated Hospital of Jiangsu Medical College and the Affiliated Hospital 6 of Nantong University), Yancheng, China
2 Department of Biological Medicines and Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, China
3 Department of Oncology, Yancheng Third People’s Hospital (The Affiliated Hospital of Jiangsu Medical College and the Affiliated Hospital 6 of Nantong University), Yancheng, China
4 Department of Pediatrics, Yancheng Third People’s Hospital (The Affiliated Hospital of Jiangsu Medical College and the Affiliated Hospital 6 of Nantong University), Yancheng, China
5 Department of Pharmacy, The Affiliated Dongtai Hospital of Nantong University, Yancheng, China
* Corresponding Author: Xuyao Zhang. Email: email; Junli Cui. Email: email; Zhe Ding. Email: email

Oncology Research https://doi.org/10.32604/or.2026.084396

Received 22 April 2026; Accepted 14 August 2026; Published online 18 August 2026

Abstract

Objectives: MET inhibitors have demonstrated clinical efficacy in several MET-driven malignancies; however, their therapeutic potential in pancreatic cancer remains insufficiently characterized. This study aimed to evaluate the antitumor activity of the selective MET inhibitor savolitinib in MET-high pancreatic cancer and to investigate the role of autophagy in the cellular response to MET inhibition. Methods: MET-high pancreatic cancer cell lines (AsPC-1 and BxPC-3) were treated with savolitinib. Cell viability, apoptosis, transcriptomic profiling, and signaling pathway analyses were performed to characterize its antitumor effects and underlying mechanisms. Autophagy induction was assessed using monodansylcadaverine (MDC) staining, transmission electron microscopy, lysosomal co-localization analysis, and western blotting of autophagy-related markers. The therapeutic efficacy of combining savolitinib with the autophagy inhibitor chloroquine was further evaluated in vitro and in BxPC-3 xenograft models. Results: Savolitinib significantly inhibited MET phosphorylation and reduced the viability of MET-high pancreatic cancer cells while inducing apoptosis, as evidenced by increased levels of cleaved PARP, cleaved caspase-3, and an elevated Bcl-2-associated X protein (Bax)/B-cell lymphoma 2 (Bcl-2) ratio. Transcriptomic analysis revealed significant enrichment of autophagy-related pathways among savolitinib-responsive genes. Savolitinib induced autophagy-associated vesicular changes and autophagic flux, accompanied by suppression of AKT/mTOR signaling. Pharmacological inhibition of autophagy with chloroquine markedly enhanced savolitinib-induced apoptosis in vitro and significantly improved tumor growth inhibition in vivo, achieving a tumor growth inhibition rate of 84.96% in the combination-treatment group without obvious systemic toxicity under the tested conditions. Conclusion: Savolitinib-induced autophagy functions as an adaptive cytoprotective response in MET-high pancreatic cancer. Combined inhibition of MET and autophagy enhances antitumor activity and warrants further evaluation in MET-high pancreatic cancer models.

Keywords

Savolitinib; pancreatic cancer; MET; autophagy; combination therapy

  • 172

    View

  • 21

    Download

  • 0

    Like

Related articles
Copyright© 2026 Tech Science Press
© 1997-2026 TSP (Henderson, USA) unless otherwise stated

Share Link